IDH2 and central nervous system cancer: In the present study, the differences in the metabolic profiles by the IDH status were analyzed in grades I–III gliomas, excluding GBMs, because all GBMs did not have a IDH mutation and because several metabolites were significantly different from other grades of gliomas.